Who Owns Amgen Company?

Amgen Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Amgen?

Understanding Amgen's ownership is key to grasping its strategic direction and influence. The company's recent $27.8 billion acquisition of Horizon Therapeutics in October 2023 significantly reshaped its market position, particularly in rare diseases.

Amgen, founded in 1980, has grown into a global biopharmaceutical leader. Its ownership is predominantly held by institutional investors and public shareholders, with a smaller portion by insiders.

The ownership structure of Amgen Inc. is primarily composed of institutional investors, holding a significant majority of the company's shares. These institutions include major asset management firms and mutual funds that invest on behalf of a broad base of individuals. Public shareholders, meaning individual investors who buy stock on the open market, also constitute a substantial portion of Amgen's ownership. Insider ownership, which refers to shares held by company executives and board members, represents a smaller but influential segment. This diverse ownership base shapes the company's governance and strategic decisions, as seen in its ongoing development and market strategies, including its work on products like those analyzed in the Amgen BCG Matrix.

Amgen, initially known as Applied Molecular Genetics Inc., was founded on April 8, 1980, in Thousand Oaks, California. The company's inception was driven by a consortium of venture capitalists, with William K. Bowes and his associates playing a pivotal role. George B. Rathmann, a scientist and businessman, was appointed as the first president and CEO in October 1980, guiding the company's scientific direction and initial fundraising efforts.

Founding Vision

Amgen was established with a focus on recombinant DNA technology. The company's early scientific advisory board included prominent researchers who guided its foundational research endeavors.

Initial Funding

The startup secured approximately $19 million in venture capital at its launch. This substantial initial investment was crucial for a biotechnology firm in its early stages.

Early Scientific Achievements

A significant early scientific accomplishment was the development of a process to produce indigo dye using E. coli. This innovation was recognized in the journal Science in 1983.

Name Change and IPO

The company officially adopted the name Amgen in 1983. This rebranding coincided with its Initial Public Offering (IPO), marking its transition to a publicly traded entity.

Venture Capital Backing

The foundational ownership structure was heavily influenced by venture capitalists. These early investors held significant stakes, underpinning the company's initial growth and operations.

Key Founding Figures

William K. Bowes was instrumental in the formation of the company. George B. Rathmann led as the first president and CEO, shaping the company's early scientific and business strategies.

The early ownership of Amgen was primarily vested in its founding venture capital firms and initial investors. While specific individual founder equity splits are not publicly detailed, the substantial venture capital infusion of approximately $19 million at its inception indicates a concentrated ownership by those who financed its early development. The company's transition to a publicly traded entity through its 1983 IPO broadened its ownership base, making it subject to public market dynamics and the influence of institutional and individual shareholders. Understanding the Marketing Strategy of Amgen provides further context on how the company has leveraged its innovations and market position since its early days.

Amgen SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Amgen's journey from a startup to a major player in the biotechnology sector was significantly shaped by its Initial Public Offering (IPO) on June 17, 1983. This event raised nearly $40 million, enabling substantial investment in research and development and paving the way for its inclusion in the S&P 500 by January 2, 1992.

The ownership structure of Amgen, a publicly traded entity, is predominantly held by institutional investors as of July 2025. These large entities, including mutual funds and investment management firms, collectively own between 76.50% and 82.06% of the company's stock. This broad institutional backing influences Amgen's strategic direction, often emphasizing long-term growth and consistent returns, aligning with the interests of a diverse shareholder base.

Understanding Amgen's Shareholder Landscape

Amgen's ownership is largely concentrated in the hands of institutional investors, reflecting its status as a mature public company. Understanding who owns Amgen provides insight into its governance and strategic priorities.

• Institutional investors hold the majority of Amgen stock, typically between 76.50% and 82.06%.
• Major institutional shareholders include The Vanguard Group, Inc. and BlackRock, Inc.
• Vanguard Fiduciary Trust Co. holds approximately 9.842% of Amgen equities.
• BlackRock Advisors LLC is another significant holder with 6.298% ownership.
• Individual insiders and employees hold a considerably smaller percentage of shares.
• The company's inclusion in the S&P 500 signifies its substantial market capitalization.
• The history of Amgen ownership shows a shift from early venture capital to broad public and institutional investment.
• Amgen company management and ownership are closely linked through board responsibilities and executive leadership.
• The responsibilities of Amgen board members include overseeing company strategy and ensuring shareholder interests are met.
• Amgen stock holders are diverse, ranging from large funds to individual retail investors.
• The Competitors Landscape of Amgen can influence its strategic decisions and ownership dynamics.

Amgen PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of May 23, 2025, Amgen's governance is overseen by a Board of Directors comprising 12 members, all elected at the 2025 Annual Meeting of Stockholders. Robert A. Bradway holds the dual roles of Chairman and Chief Executive Officer, guiding both the board and the company's executive operations. The board is structured with a blend of independent directors and individuals possessing substantial industry acumen.

Amgen operates under a voting system where each common share is entitled to one vote, ensuring a uniform voting power among shareholders. The company's bylaws include provisions for proxy access, allowing eligible stockholders who own at least 3% of the company's stock for a minimum of three years to nominate directors. This mechanism aims to give shareholders a direct influence on the board's composition. At the 2025 Annual Meeting of Stockholders, approximately 87.3% of outstanding shares were represented, with all director nominees securing a majority of the votes cast in their favor. Furthermore, an advisory vote on executive compensation received strong support, with over 94% of votes cast approving the proposal. The company's governance principles emphasize board independence, outlining qualifications and evaluation criteria for directors, with the Governance and Nominating Committee playing a key role in identifying and recommending candidates. For a deeper understanding of the company's journey, explore the Brief History of Amgen.

Shareholder Influence and Board Governance

Amgen's corporate governance framework is designed to balance management's strategic direction with shareholder interests. The voting structure and proxy access provisions empower stockholders in key decisions.

• One-share-one-vote principle ensures equal voting rights.
• Proxy access allows eligible shareholders to nominate directors.
• High attendance at the 2025 Annual Meeting signifies shareholder engagement.
• Overwhelming approval for executive compensation reflects confidence in leadership.

Amgen Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past 3-5 years, Amgen's ownership profile has been shaped by significant strategic acquisitions and the enduring influence of institutional investors. A key development was the acquisition of Horizon Therapeutics, a deal valued at $27.8 billion, which was finalized in October 2023 after regulatory review. This move significantly enhanced Amgen's rare disease and inflammation portfolios.

Institutional investors maintain a substantial stake in Amgen, holding between 76.50% and 82.06% of the company's stock as of late 2024 and mid-2025. This dominance by entities like The Vanguard Group and BlackRock underscores the significant influence of large financial institutions on Amgen's shareholder base. While individual insider ownership is modest, ranging from 0.19% to 0.76%, insider transactions, such as share sales by executives, do occur. The company's strategic direction, including its focus on expanding its pipeline through acquisitions, aligns with broader industry trends towards consolidation and the pursuit of innovative therapies. Amgen's financial performance, with reported 2024 revenues of $33.4 billion and projected revenues between $32.5 billion and $33.8 billion for the same year, reflects the impact of these strategic initiatives and the company's commitment to long-term growth under its current leadership.

Institutional Investor Dominance

Institutional investors, including The Vanguard Group and BlackRock, hold the majority of Amgen's shares. This concentration of ownership signifies their significant influence on the company's strategic decisions and governance.

Strategic Acquisition Impact

The acquisition of Horizon Therapeutics for $27.8 billion in 2023 bolstered Amgen's rare disease pipeline. This move exemplifies industry trends and Amgen's strategy for growth through acquiring innovative treatments.

Financial Performance and Growth

Amgen reported $33.4 billion in revenue for 2024, with projections for the year between $32.5 billion and $33.8 billion. This financial strength supports the company's ongoing strategic initiatives and commitment to innovation.

Leadership and Management

Led by Chairman and CEO Robert A. Bradway, Amgen's executive leadership focuses on delivering innovative medicines. Understanding the Target Market of Amgen is crucial for appreciating the company's strategic direction and management's decision-making.

Amgen Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔